In his first address to a joint session of Congress, President Donald Trump made a dramatic appeal for lowering the hurdles new medicines face in gaining approval from the Food and Drug Administration. But Trump’s promises – that reduced regulatory standards would result in more cures reaching the market and lower drug prices – may be hard to keep.
